Treatment of Herpes Zoster (Shingles) in Adults
Start oral antiviral therapy immediately—ideally within 72 hours of rash onset—with valacyclovir, famciclovir, or acyclovir, and provide adequate pain management to reduce acute symptoms and prevent postherpetic neuralgia.
Antiviral Treatment
The cornerstone of shingles treatment is prompt antiviral therapy. Begin treatment as soon as possible, preferably within 72 hours of rash appearance 1, 2. The evidence consistently supports three oral antiviral options:
- Valacyclovir (preferred for convenience)
- Famciclovir (preferred for convenience)
- Acyclovir (requires more frequent dosing)
All three medications have demonstrated efficacy in reducing viral replication, accelerating healing, and decreasing the risk of postherpetic neuralgia 1, 2.
Treatment Duration and Escalation
Continue oral antivirals for 7-10 days or until all lesions have completely healed 3, 1. For uncomplicated cases, oral therapy is sufficient 3.
For severe or complicated disease, switch to intravenous acyclovir 3:
- Disseminated herpes zoster
- Herpes zoster ophthalmicus (eye involvement)
- Herpes zoster oticus (ear involvement)
- Neurological complications
- Immunocompromised patients with extensive disease
IV acyclovir dosing: 5-10 mg/kg every 8 hours until clinical improvement, then transition to oral therapy to complete 14-21 days total treatment 3.
Pain Management
Adequate analgesia is critical both for symptom control and to reduce the risk of developing postherpetic neuralgia 4, 5. Use a stepwise approach:
Acute Phase Pain
- NSAIDs for mild pain
- Opioids for moderate to severe pain (short-term use during acute phase)
- Topical therapies can be added as adjuncts
Neuropathic Pain Components
If neuropathic pain is prominent even in the acute phase, consider early addition of:
- Gabapentinoids (gabapentin or pregabalin) 1, 4
- Tricyclic antidepressants 1
- Serotonin-norepinephrine reuptake inhibitors 1
Special Populations Requiring Aggressive Treatment
Immunocompromised patients require both IV acyclovir AND temporary reduction in immunosuppressive medications 3. This includes:
- Transplant recipients
- HIV-infected individuals
- Patients on chronic immunosuppressive therapy
Patients with ophthalmic involvement (herpes zoster ophthalmicus) require immediate ophthalmology consultation in addition to antiviral therapy 6.
Common Pitfalls to Avoid
Delaying treatment beyond 72 hours: While antivirals can still provide benefit after 72 hours, efficacy decreases significantly. Treat based on clinical suspicion even before laboratory confirmation.
Inadequate pain control: Undertreating acute pain increases the risk of developing chronic postherpetic neuralgia, which occurs in 10-18% of patients overall and up to 50% in those over 85 1, 4.
Using topical acyclovir: Topical antiviral therapy is substantially less effective than oral medications and should not be used 7.
Stopping treatment too early: Continue until all lesions have completely crusted over and healed 3.
Postherpetic Neuralgia Prevention and Treatment
Postherpetic neuralgia (PHN) is defined as dermatomal pain persisting beyond 90 days after rash onset 1, 2. Early, aggressive antiviral and analgesic treatment reduces PHN risk.
If PHN develops, first-line treatments include 1:
- Gabapentinoids (gabapentin or pregabalin)
- Tricyclic antidepressants
- Serotonin-norepinephrine reuptake inhibitors
- Topical lidocaine or capsaicin as adjunctive therapy
Prevention Through Vaccination
While not treatment per se, strongly recommend recombinant zoster vaccine (RZV/Shingrix) for all adults 50 years and older 6, 8. RZV has 96% efficacy compared to 70% for the older live vaccine 6. For immunocompromised adults, vaccination is recommended starting at age 18 9.
Patients can receive vaccination at least 2 months after an acute herpes zoster episode to prevent recurrence 8.